Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

VYNE

VYNE News

Newswire

05:25

VYNE shares surge 13.10% premarket after Q3 loss narrows, revenue beats estimates, and cost reductions extend cash runway into 2027.

16:17

VYNE shares rise 13.19% after-hours as Q3 loss beats estimates and revenue tops forecasts, with strategic review underway to boost shareholder value.

08:35

VYNE Therapeutics Reports Q3 Results, Cash Runway into 2027

08:07

VYNE Therapeutics reports Q2 results, evaluates pipeline opportunities.

15:08

Aquestive Therapeutics Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Falls Short at $10 Million

View More

About VYNE

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More